Select Page

The 4th Tregitope Collaborator Meeting will be held at Hotel Providence on May 11 2011.

Registration can be made online. The Tregitope Update is co-located with and incorporated into Immunogenicity Determinants and Correlates meeting (click here for more information), and included in the IDC Registration fee.

Registration is now open at: Immunogenicity Determinants and Correlates Regonline

This will be the 4th annual meeting of Tregitope collaborators.

Tregitopes are small peptidic regulatory T-cell epitopes derived from human immunoglobulins that activate regulatory T cells (Tregs). Tregitope therapy has broad-reaching implications, offering new treatments for autoimmune diseases (e.g. type 1 juvenile diabetes, multiple sclerosis, rheumatoid arthritis, and lupus), allergies, and transplantation rejection.

Tregitopes may reduce or eliminate anti-drug responses, leading to more effective therapies against Pompe’s disease, Fabry’s disease, blood clotting disorders (hemophilia), or cancer, where treatment efficacies are sharply limited by immune responses against therapy. Tregitopes may also reduce or prevent immune responses to gene therapy vectors based on recombinant adeno-associated virus (AAV). Such responses can abort expression of therapeutic genes limiting the effectiveness of Gene Transfer (also known as Gene Therapy).

In previous meetings, the members of the Tregitope Collaborators team have demonstrated the immune suppressive capacity of Tregitopes. Ongoing research in the laboratories of the collaborators seeks to define the mechanism by which Tregitopes regulate immune responses and thereby accelerate the translation of this novel therapy to the clinic.

Speakers will include Anne S. De Groot, M.D. (EpiVax); Nader Najafian, M.D. (Brigham and Women’s Hospital (BWH)); Federico Mingozzi, Ph.D. (Children’s Hospital of Philadelphia (CHOP)); and Samia Khoury, M.D. (BWH).

Each of these investigators will report on a different but related facet of Tregitope action – modulation of antigen-presenting cells (APCs), CD4+, CD8+, and Th17-mediated immune responses). Additional speakers include: David W. Scott, Ph.D. (Uniformed Services University of the Health Sciences, Bethesda, MD), Mo Sayegh, M.D. (Harvard-BWH), and Katherine High, M.D. (CHOP).

This meeting is open, but registration is required.


Tregitope Update: Wednesday – May 11, 2011

Times Presenter(s) Subject(s)

9:30 REGISTRATION and BREAKFAST
10:00 AM-

10:20 AM

Tregitope Overview –  Annie De Groot, CEO, EpiVax

10:30 AM-

11:00 AM

Leslie Cousens, EpiVax – Tregitopes: Mechanisms and Delivery (confirmed)
11:10 AM-

11:40 AM

Nadar Najafian, BWH – Alloimmunity and Transplant Tolerance (confirmed)
11:50 PM-

12:30 PM

Federico Mingozzi, Children’s Hospital of Philadelphia (CHOP) – Modulation of AAV vectors immunogenicity

12:30 PM-

1:30 PM

LUNCH BREAK- LUNCH POSTER SESSION- WITH TRIAD Joint Lunch with TRIAD Toolkit Trainees
1:30 PM-

1:50 PM

Wassim Elyaman/Samia Khoury, BWH – Tregitopes, Th17 and EAE (confirmed)
2:00 PM-

2:20 PM

Tregitope Collaborators (Final Speaker to be Identified)

Andrew Issekutz, Dalhousie University

Ziad Mallet, INSERM

Benoit Salomon, CERVI

Mark Carvlin, CardioVax

2:30 PM-

3:00 PM

GROUP DISCUSSIONS – D. SCOTT/ A . De GROOT Moderating
3:00 PM CLOSING REMARKS (END OF PUBLIC MEETING)
3: 30-5 00 PM

Closed meeting of Tregitope Collaborators –  FUTURE DIRECTIONS